

PCDH10 Promoter Hypermethylation is Frequent in most Histologic Subtypes of Mature Lymphoid Malignancies and Occurs Early in Lymphomagenesis

Gopeshwar Narayan,^{1†} Dongxu Xie,² Allen J. Freddy,¹ Ganchimeg Ishdorj,² Catherine Do,² Prakash Satwani,³ Hema Liyanage,⁴ Lorraine Clark,¹ Sergey Kisselev,¹ Subhadra V. Nandula,^{1‡} Luigi Scotti,⁵ Bachir Alobeid,¹ David Savage,⁵ Benjamin Tycko,^{1,2} Owen A. O'Connor,⁵ Govind Bhagat,¹ and Vundavalli V. Murty^{1,2*}

¹Department of Pathology and Cell Biology, Columbia University Medical Center, New York Presbyterian Hospital, New York, NY

²Institute for Cancer Genetics, Irving Cancer Research Center, Columbia University Medical Center, New York, NY

³Department of Pediatrics, Columbia University Medical Center, New York, NY

⁴Applications and Technology Division, Sequenom, Inc. San Diego, CA

⁵Department of Medicine, Columbia University Medical Center, New York, NY

PCDH10 is epigenetically inactivated in multiple tumor types; however, studies in mature lymphoid malignancies are limited. Here, we have investigated the presence of promoter hypermethylation of the PCDH10 gene in a large cohort of well-characterized subsets of lymphomas. PCDH10 promoter hypermethylation was identified by methylation-specific PCR in 57 to 100% of both primary B- and T-cell lymphoma specimens and cell lines. These findings were further validated by Sequenom Mass-array analysis. Promoter hypermethylation was also identified in 28.6% cases of reactive follicular hyperplasia, more commonly occurring in states of immune deregulation and associated with rare presence of clonal karyotypic aberrations, suggesting that PCDH10 methylation occurs early in lymphomagenesis. PCDH10 expression was down regulated via promoter hypermethylation in T- and B-cell lymphoma cell lines. The transcriptional down-regulation resulting from PCDH10 methylation could be restored by pharmacologic inhibition of DNA methyltransferases in cell lines. Both T- and B-cell lymphoma cell lines harboring methylation-mediated inactivation of PCDH10 were resistant to doxorubicin treatment, suggesting that hypermethylation of this gene might contribute to chemotherapy response. © 2013 Wiley Periodicals, Inc.

INTRODUCTION

The protocadherin subfamily of the cadherin superfamily of genes that encode cadherin-related neuronal receptors plays a role in the establishment and function of specific cell-cell connections (Yagi, 2008). *PCDH10*, a member of this family, has been implicated as tumor suppressor gene by epigenetic inactivation in multiple human cancer types (Ying et al., 2006, 2007; Narayan et al., 2009; Yu et al., 2009; Cheung et al., 2010) and promoter CpG island hypermethylation-associated *PCDH10* gene silencing is a frequent event in myeloid and lymphoid leukemias (Garcia-Manero et al., 2009; Narayan et al., 2011). However, data regarding the role of *PCDH10* in mature lymphoid malignancies are limited. Few reports have shown high frequency of *PCDH10* methylation and associated down-regulation of expression in a limited panel of T- and B-cell lymphoma cell lines and primary tumors (Ying et al., 2007; Li et al., 2012).

Epigenetic processes, most notably patterns of DNA promoter sequence hypermethylation, play

a central role in cellular transformation and treatment of cancer. Specific genetic mutations that confer chromatin modifications at certain loci have led to the development of therapies influencing the epigenetic landscape in leukemia (Nowak et al., 2009; Baylin and Jones, 2011). Although similar advances in malignant lymphoma are lacking, recently there has been an intense growing interest in understanding the role of epigenetic modifications in lymphoid malignancies (Zain and O'Connor, 2010; Seton-Rogers, 2012).

Additional Supporting Information may be found in the online version of this article.

*Correspondence to: Vundavalli V. Murty, Irving Cancer Research Center, Room 605, Columbia University Medical Center, 1130 St. Nicholas Avenue, New York, NY 10032, USA. E-mail: vvm2@columbia.edu

Supported by: Lance Armstrong Foundation (to V.V.M.).

†Present address: Banares Hindu University, Varanasi, India.

‡Present address: Cancer Genetics, Inc, Rutherford, NJ.

Received 17 March 2013; Accepted 7 July 2013

DOI 10.1002/gcc.22098

Published online 9 August 2013 in Wiley Online Library (wileyonlinelibrary.com).

Here, we have examined the presence of promoter hypermethylation of *PCDH10* in various histologic subtypes of non-Hodgkin lymphoma (NHL) and found high frequency methylation in most lymphoma cases. Promoter hypermethylation resulted in down-regulated expression of *PCDH10* in lymphoma cell lines, and cell lines carrying *PCDH10* promoter methylation or down-regulated expression exhibited resistance to doxorubicin treatment. Furthermore, the presence of *PCDH10* hypermethylation in a significant fraction of reactive lymph nodes suggests that promoter methylation might be an early event in lymphomagenesis.

MATERIALS AND METHODS

Patient Samples and Cell Lines

A total of 292 DNA samples from 291 patients derived from primary tumors diagnosed at our institute over a 12-year period (July 1997–June 2009) were analyzed, which represented 21 reactive lymph (RL) nodes exhibiting follicular hyperplasia (FH), 50 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 19 Burkitt lymphomas (BL), 39 follicular lymphomas (FL), 41 diffuse large B-cell lymphomas (DLBCL), 38 marginal zone lymphomas (MZL), 16 mantle cell lymphomas (MCL), 35 multiple myelomas (MM), and 33 T/NK-cell lymphomas. All specimens used in this study were evaluated by morphology, flow cytometry, and cytogenetic analyses (Supporting Information Table 1) and classified according to the current WHO criteria (Swerdlow et al., 2008). All lymphoma cases were selected to obtain >40% tumor cells either by morphology and/or fluorescence in situ hybridization (FISH) positivity. In addition, 10 T-cell lymphoma cell lines (MT1, MT2, ED, C/JM5, TLOm1, SLB1, HH, H9, HUT-78, and FE-PD) and 10 B-cell lymphoma cell lines (Raji, Daudi, LY-1, LY-3, SU-DHL-4, SU-DHL-5, SU-DHL-8, SU-DHL-10, WSU, and Farage) (kindly provided by Riccardo Dalla-Favera, Columbia University, New York) were also utilized. All cell lines were grown in RPMI-1640 or IMDM medium containing 10 to 15% fetal bovine serum. Our institutional review board approved the study protocol.

DNA and RNA Isolation

Frozen specimens and cell lines were utilized for isolation of high molecular weight DNA and RNA by standard methods. RNA quality and quantity was assessed by a bioanalyzer (Agilent Technologies, Foster City, CA).

Methylation Specific PCR (MSP)

Two micrograms of genomic DNA was converted using EpiTect 96 bisulfite kit (Qiagen, Valencia, CA). Placental DNA treated in vitro with *SssI* methyltransferase (New England BioLabs, Beverly, MA) and normal lymphocyte DNA converted with sodium bisulfite was used as methylated and unmethylated controls, respectively. Four sets of primers utilized for amplification of methylated (M) DNA and two sets of primers for unmethylated (U) DNA spanning two CpG islands (CGIs) of cDNA clone NM-032961 were described previously (Narayan et al., 2009, 2011). PCR was performed using standard conditions for 30~35 cycles with annealing temperatures varying between 56 and 62°C. All MSP experiments were performed in triplicate and promoter hypermethylation was considered positive when present in at least one of the regions in replicate experiments.

Sequenom EpiTyper Quantitative Methylation Analysis

Quantitative methylation analysis was performed using the Sequenom MALDI-TOF mass spectrometry platform as per manufacturer specifications (Sequenom, Inc. San Diego, CA) and as described previously (Narayan et al., 2011). Heat maps were generated by using either R-script or JMP genomics software (<http://www.jmp.com/software/genomics/>).

Drug Treatment

Cells in culture were treated with 5 μ M 5-aza-2'-deoxycytidine (5-aza-CdR) for 5 days by replacing the medium everyday, trichostatin (TSA) at a final concentration of 200 nM for 24 hr and combination of both as previously described (Narayan et al., 2009). Cells collected from these experiments were used for isolating total RNA. We determined ICD50 values for all NHL cell lines for the drugs used and the following final concentrations were used in the present experiments: doxorubicin (15 ng/ml), dexamethasone (100 nM), bortezomib (2 ng/ml), methotrexate (50 nM), and L-asparaginase (2 U/ml). Cell lines were treated with these drugs for 48 hr to assess cell viability and apoptosis.

Reverse Transcription PCR (RT-PCR) and Western Blot Analysis

Total RNA isolated from cell lines was reverse transcribed as described (Narayan et al., 2009). Semiquantitative expression of *PCDH10* was

performed in triplicate RT-PCR experiments using the primers described previously and standard thermal cycle conditions (Narayan et al., 2011). The β -actin gene was used as control to assess the relative intensity of mRNA expression. Western blot analysis was performed by standard methods using polyclonal PCDH10 antibody (Thermo Scientific, Rockford, IL) and a secondary antibody conjugated with horseradish peroxidase (Bio-Rad, Hercules, CA). Detection was performed by ECL-Western Lightning Chemiluminescence reagent (Amersham Pharmacia) and the blot was re-probed with β -actin as control.

Cell Viability and Apoptosis Assays

Cell viability and cytotoxicity due to each drug was assessed by standard MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Invitrogen, Carlsbad, CA) colorimetric assay. Briefly, 5,000 cells were seeded in 96-well cell culture plates, grown overnight at 37°C in 5% CO₂ incubator, and treated with drugs for 48 hr. After incubation of cells in 5 mg/ml of MTT in phosphate buffer saline for 3.5 hr, medium was removed, the dye was dissolved in 150 μ l of MTT solvent and the optical density of solubilized formazan was assessed using a microplate reader (Bio-Tek Quant, Winooski, VT). All treatments were performed in four replicate wells in two independent experiments. To measure apoptosis, we used Pacific Blue™ Annexin V/SYTOX® AADvanced™ Apoptosis Kit (Invitrogen). Briefly, 0.5 to 1.0 million cells were seeded in 48-well tissue culture plates, grown overnight at 37°C at 5% CO₂ incubator, and the indicated concentration of drugs was added. Cells collected after 48 hr of incubation were analyzed by a LSR II flow cytometer (BD Biosciences, San Jose, CA) using 405 nm and 488 nm excitation and 455 nm and 647 nm emissions. A total of 20,000 events were analyzed using Flowjo software (Tree Star, OR) in duplicate experiments.

Karyotype and Fluorescence In Situ Hybridization (FISH) Analyses

G-band karyotype and FISH analyses were performed using standard methods.

Statistical Analysis

ANOVA and *t*-test statistics were calculated using the GraphPad Prism software (LaJolla, CA).

TABLE 1. Frequency of *PCDH10* Promoter Hypermethylation in Mature B- and T-Cell Lymphomas

Histologic subtype	No. Studied	Methylated (%)
Reactive lymph node/follicular hyperplasia	21	6 (29%)
Chronic lymphocytic leukemia	50	33 (66%)
Burkitt's lymphoma	19	18 (95%)
Follicular lymphoma	39	39 (100%)
Diffuse large B-cell lymphoma	41	41 (100%)
Marginal zone lymphoma	38	34 (90%)
Mantle cell lymphoma	16	15 (94%)
Multiple myeloma	35	20 (57%)
Natural killer (NK)/T-cell lymphoma	33	26 (79%)

RESULTS

MSP Analysis Identifies High Frequency of *PCDH10* Promoter hypermethylation in Various Histologic Subtypes of Non-Hodgkin Lymphomas and Multiple Myeloma

The *PCDH10* gene promoter region spanning two classic CpG islands was examined by MSP for qualitative assessment of methylation as previously described (Supporting Information Fig. 1A) (Narayan et al., 2011). Promoter methylation analysis was performed on a total of 292 DNA samples derived from various histologic subtypes of B- and T-cell lymphomas (Table 1). Among the B-cell NHL, promoter hypermethylation was found in all 39 (100%) FL and 41 (100%) DLBCL, 18 (95%) of 19 BL, 15 (94%) of 16 MCL, 34 (90%) of 38 MZL, 33 (66%) of 50 CLL, and 20 (57%) of 35 MM samples (Table 1). Among the 33 T- and NK-cell lymphomas examined, 26 (79%) showed promoter hypermethylation (Table 1). Similar analysis on DNA isolated from 21 specimens of reactive follicular hyperplasia revealed hypermethylation in six (29%) cases. Of note, 11 of these cases occurred in individuals with known immune deregulation and five displayed minor clonal karyotypic abnormalities. Therefore, these data provide evidence that a large majority of cases across all major histologic subtypes of lymphomas harbor *PCDH10* promoter hypermethylation and suggest that inactivation of this gene may be related to disease pathogenesis. The presence of promoter hypermethylation in reactive lymph nodes suggests that DNA methylation modifications in *PCDH10* might be an early event in lymphomagenesis (Table 1). To examine if methylation is uniformly present across the two CGIs or is restricted to specific regions within a CGI, we compared the patterns of MSP of the four regions

studied in each specific subtype of lymphoma. This analysis revealed that promoter methylation was restricted to smaller segments in CGIs in cases of CLL and MM compared with extensive methylation in other histologic subtypes (Supporting Information Fig. 1B).

Validation of Promoter Methylation by Quantitative High-Throughput MALDI-TOF MS Analysis

To validate the MSP data and for quantitative assessment of methylation, we analyzed 196 samples (20 RL/FH, 12 BL, 25 FL, 26 DLBCL, 38 MZL, 13 MCL, 27 MM, 14 CLL, and 21 T-/NK cell) that were also analyzed by MSP, utilizing high throughput MALDI-TOF MS methylation analysis (Sequenom). For this analysis we chose CpG Island 2 (CGI-2) covering 78 CpG sites in three amplicons (Supporting Information Fig. 1A). Of these, 47 CpG sites, which include single CpG sites and multiple CpGs that fall in one fragment, were considered informative after MALDI-TOF MS read out and quality control analysis. Methylation fraction per CpG was calculated as described previously (Narayan et al., 2011). Mean \pm SEM was 0.2018 ± 0.03 for RL/FH specimens, 0.2293 ± 0.03 for CLL, 0.2082 ± 0.03 for MM, 0.3193 ± 0.05 for MCL, 0.4109 ± 0.04 for DLBCL, 0.5483 ± 0.04 for BL, 0.3565 ± 0.03 for FL, 0.3486 ± 0.02 for MZL, and 0.3094 ± 0.04 for T-/NK cell cases (Fig. 1A). Differences in methylation levels between RL/FH samples and CLL ($P = 0.46$) or MM ($P = 0.88$) were not statistically significant, while other histologic subtypes (BL, DLBCL, FL, MZL, MCL, and T-NHL) showed significant differences compared with RL/FH samples (Fig. 1A). The levels of methylation were highest in BL samples ($P = 0.0001$) among all the histologic subtypes (Figs. 1A and 1B). Supervised one-way hierarchical cluster analysis of RL/FH samples in combination with each histologic subtype of NHL cases resulted in two or more major clusters depending on the levels of methylation (Fig. 1B, Supporting Information Fig. 2). In the present analysis, we classified the top two clusters as clusters 1 and 2, which contained cases harboring the highest levels of methylation, and the remaining cases into one group. This analysis showed that all the 12 cases of BL were present in cluster 1 or 2, while only 4 of the 20 samples of RL/FH were present in clusters 1 and 2. These data suggest that *PCDH10* promoter methylation is high in BL samples as compared with RL/FH

samples (Fig. 1B, top panel). Similarly, a large majority of samples from DLBCL, FL, MZL, MCL, and T-NHL were grouped in cluster 1 or 2 along with 3 to 4 samples of RL (Fig. 1 and Supporting Information Fig. 2). Nonsupervised cluster analysis of all the samples together further confirmed these findings where the same four RL/FH samples were grouped with highest methylated lymphoma cases while the remaining 16 RL/FH cases clustered with samples harboring low methylation (Supporting Information Fig. 3). On the other hand, only few samples from MM and CLL appeared in cluster 1 and 2 along with three to four samples of RL/FH (Supporting Information Fig. 2). This observation is consistent with the MSP data showing localized methylation in CLL and MM samples. These data further suggest that the *PCDH10* promoter methylation levels vary in different histologic subtypes of NHL.

PCDH10 Promoter Methylation Occurs Early in Lymphomagenesis

As shown above, 29% of lymph nodes exhibiting RL/FH displayed promoter hypermethylation by MSP compared with >50% of cases in NHL histologic subtypes and multiple myeloma (Table 1). Similarly, Sequenom methylation analysis showed 0.2018 fraction of CpG methylation in RL/FH lymph nodes. This level of methylation in RL/FH is lower than most histologic subtypes of mature lymphomas (Fig. 1 and Supporting Information Fig. 2) and higher than normal bone marrow samples (3.6% by MSP and 0.115 methylation fraction by Sequenom analysis) as reported previously (Narayan et al., 2011). These data suggest that *PCDH10* promoter methylation occurs early in lymphoma development. As stated above, hierarchical cluster analysis of Sequenom MALDI-TOF MS methylation data identified the same 4 of 20 RL/FH samples clustered with several histologic subtypes of lymphoma samples exhibiting higher methylation (Fig. 1B and Supporting Information Figs. 2 and 3). This observation implies that these 4 reactive lymph nodes harbor *PCDH10* promoter methylation similar to high-grade lymphomas such as BL, DLBCL and MZL.

Of the 4 RL/FH samples that showed higher methylation, 2 specimens were obtained from the same patient's adenoids and tonsils with previous history of liver transplant and exhibited florid follicular hyperplasia, without any evidence of NHL. These 2 samples consistently grouped in cluster 1 or 2 by nonsupervised analysis. The adenoid




Figure 1. Quantitative analysis of methylation of *PCDH10* promoter region in reactive lymphoid hyperplasia and various subtypes of lymphoma using Sequenom EpiTYPER. (A). Box-plot showing methylation fraction in various lymphoma subtypes. Significant differences between RL/FH and histologic subtype of lymphoma are shown by *P* value. Box plot shows median, 25th and 75th percentile, minimum and maximum values. (B). Heat maps showing one dimensional cluster analysis of methylation data generated by Sequenom's MassArray and EpiTyper (left panel) between reactive lymph nodes analyzed with BL, DLBCL, or MZL. Histogram shows number of cases present in each cluster

(right panel). CpG Units are arranged along the x-axis and samples are on the y-axis. Right brackets in left panel indicate clusters of methylated cases. Missing data values are annotated in gray. The red and yellow scale at the bottom represents the percentage methylation with dark red as lowest methylation and dark yellow as highest (~100%) methylation. BL, Burkitt lymphoma; C, cluster; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; RL/FH, reactive lymph node/follicular hyperplasia; FL, follicular lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma; MZL, marginal zone lymphoma; T-NHL, T-cell Non-Hodgkin lymphoma.

sample showed a mean methylation fraction of 0.63 and the tonsil 0.45 by Sequenom methylation analysis, which is similar to the methylation levels seen in high-grade lymphomas (Fig. 1B and Supporting Information Figs. 2 and 3). Karyotype analysis identified the same chromosomal translocation [t(1;14)(q21;q32)] in both adenoids and tonsils with the adenoids demonstrating a nonclonal (1 of 41 metaphases) abnormality, while the tonsils

exhibited a minor clone (3 of 40 metaphases) harboring this translocation (Fig. 2A). The t(1;14)(q21;q32) was reported in post-transplant RL/FH (Vakiani et al., 2007) and has been shown to be an early event in lymphomagenesis of mature B-cell lymphomas. The breakpoint at 14q32 is being the site of the immunoglobulin heavy chain (*IGH*) (Pinkerton et al., 1992; Dyomin et al., 2000). FISH analysis using *IGH* break apart




Figure 2. Cytogenetic analysis of a case of tonsils sample diagnosed as follicular hyperplasia and subsequently progressed to post-transplant lymphoproliferative disorder (PTLD) on follow-up. (A). A G-banded karyotype from tonsils showing $t(1;14)(q21;q32)$ as indicated by arrows. (B). FISH analysis showing IGH rearrangement in PTLD. Yellow arrow indicates intact IGH locus. Red and green arrows indicated rearranged IGH.

TABLE 2. Histologic, Cytogenetic Abnormalities, and Methylation Changes Seen in Reactive Lymph Nodes Exhibiting High Promoter Methylation of *PCDH10*

S. No.	Case	Tissue	Diagnosis	Methylation		Karyotype	FISH (% +ve)	
				MSP	MassArray		IGH	+3
1	RL305	Adenoids	FH	M	0.63	46,XY,t(1;14)(q21;q32)[1]/46,XY[40]	0.8	ND
	RL306	Tonsils	FH	M	0.45	46,XY,t(1;14)(q21;q32)[3]/46,XY[57]	1.8	ND
	F/U LN1294	LN-1	PTLD	ND	ND	46,XY,t(1;14)(q21;q32)[15]/47,XY,+3[5]	20.4	16.0
	F/U LN1295	LN-2	PTLD	ND	ND	46,XY,t(1;14)(q21;q32)[11]/47,XY,+3[10]/46,XY[2]	20.3	13.8
2	RL575	LN	FH	M	0.32	46,XX[20]	0	ND
3	RL717	Tonsil	FH	M	0.23	46,XY,t(5;14)(q31;q32)[1]/47,XY,+i(1)(q10),+11,-19[1]/46,XY[18]	0	ND

FISH, fluorescence in situ hybridization; FH, follicular hyperplasia; F/U, follow-up; LN, lymph node; M, methylated; MSP, methylation specific PCR; ND, not done; PTLD, post-transplant lymphoproliferative disorder.

probe (Vysis, Des Plaines, IL) showed low frequency of rearrangement in both tonsils (1.8%) and adenoids (0.8%). After 8 months of follow-up, the patient presented with axillary and cervical lymph node enlargement due to development of a polymorphic post-transplant lymphoproliferative disorder (PTLD), which was associated with $t(1;14)$ and an additional distinct cytogenetic abnormality (trisomy 3) as major clones (Table 2; Supporting Information Fig. 4A). The karyotypic abnormalities were confirmed by FISH using IGH break apart and centromere 3 probes (Vysis) (Fig. 2B and Supporting Information Fig. 4B). The axillary lymph node showed IGH rearrangement in 20.4% cells and trisomy 3 in 16% cells, while the cervical lymph node exhibited 20% cells with IGH rearrangement and trisomy 3 in 14% cells (Table 2). Methylation analysis on the follow-up

PTLD specimens could not be performed due to lack of tissue availability. This case highlights the fact that the methylation fraction in the RL/FH sample was similar to the level seen in frank lymphomas while the chromosome aberration was presenting a very low frequency that was almost undetectable by FISH analysis. These data therefore suggest that the onset of promoter hypermethylation likely occurred prior to the origin of the chromosome abnormality in this case and indicate that *PCDH10* methylation and potentially other genes might precede chromosomal translocations in the development of lymphoma.

The third RL/FH specimen that showed high-level of promoter methylation of *PCDH10*, which occurred in an individual with FH, also demonstrated a nonclonal cytogenetic abnormality by karyotype, while FISH using IGH break apart




Figure 3. Promoter methylation and expression analysis of PCDH10 in NHL cell lines. (A). Methylation-specific PCR analysis of PCDH10 in B- (top panel) and T- (bottom panel) NHL cell lines. MSP, methylation specific PCR; U, unmethylated primer; M, methylated primer. (B). Western blot showing PCDH10 protein expression. (C).

Analysis of mRNA expression by RT-PCR analysis to identify the effects of treatment using inhibitors of methylation and HDAC in T-NHL cell lines. A, azacytidine; ACTB, beta actin; A/T, azacytidine/trichostatin; T, trichostatin; U, untreated; V1, variant 1.

probe was negative (Table 2). The fourth specimen with high levels of methylation occurred in an individual with RL and showed neither a karyotypic abnormality nor an IGH rearrangement. No follow-up specimens from these two cases were available. Of note, all the RL/FH samples that showed a high methylation index were also positive by MSP analysis.

PCDH10 Promoter Hypermethylation Correlates with Down-regulated Expression and Pharmacologic Inhibition of DNMTs Reactivates its Expression in NHL Cell Lines

Since a large proportion of primary B- and T-NHL cases harbored promoter methylation, we examined the status of *PCDH10* promoter hypermethylation in NHL cell lines. We tested 10

B-NHL cell lines and 10 T-NHL cell lines by the MSP method. All the 20 cell lines exhibited promoter methylation of one or both CGIs. Of the 10 B-NHL cell lines examined, both alleles were methylated in both CGIs in all cell lines except one. The cell line Farage showed presence of both methylated and unmethylated alleles in CGI-2 (Fig. 3A, top panel). Among the T-NHL cell lines, six cell lines (MT1, MT2, ED, TLom1, HH, and FE-PD) showed only methylated alleles in both CGI-1 and CGI-2. The remaining 4 T-NHL cell lines (CJ/M5, SLB1, H9, and HUT-78) showed both methylated and unmethylated alleles in CGI-1 or CGI-2 (Fig. 3A, bottom panel). The cell lines H9 and HUT-78 exhibited both CGIs with heterozygous methylation, while the cell lines CJ/M5 and SLB1 showed unmethylated CGI-1 and heterozygous methylation in CGI-2.

To examine the transcription levels of *PCDH10* in NHL cell lines, we performed RT-PCR analysis of two *PCDH10* transcript variants (Variant 1 spanning exons 1 and 3; Variant 2 with a single exon) on all cell lines. Since variant 2 is a single intronless exon, RNA isolated from the cell lines was treated with DNase to avoid DNA amplification. All the 10 B-NHL cell lines examined failed to show any detectable levels of expression of variant 1, while the variant 2 was detected in three cell lines (Raji, SUDHL-5, and LY-3). Of the 10 T-cell NHL cell lines, three (MT1, TLOm1, and HH) showed no detectable expression of both variants. Detectable transcripts of only variant 2 were found in four cell lines (MT2, CJ/M5, ED, and SLB1) while variant 1 was undetectable. The remaining three cell lines (H9, HUT-78, and FE-PD) showed detectable levels of expression of both variants. Western blot analysis further confirmed that the protein levels of PCDH10 were lacking or down-regulated in all B- and T-NHL cell lines compared with actin control (Fig 3B). Sixteen cell lines showed very low expression, while the remaining four cell lines (Daudi, Raji, SLB1, and ED) showed relatively higher expression. These data support the notion that *PCDH10* expression is down regulated in relation to promoter hypermethylation in the majority of NHL cell lines. The cell line data combined with the data on primary NHL specimens confirm that *PCDH10* promoter hypermethylation is a common phenomenon in mature lymphoma and multiple myeloma.

Since down-regulated or complete lack of expression of *PCDH10* variant 1 was found in 17 of 20 NHL cell lines, we treated six T-NHL cell lines (MT1, MT2, CJ/M5, ED, TLOm1, and SLB1) by the DNA demethylating agent 5-aza-CdR and the HDAC inhibitor TSA to test the reactivation of variant 1. Semi-quantitative RT-PCR analysis exhibited reactivation of the *PCDH10* gene after 5-aza-CdR alone or in combination with TSA in all six cell lines (Fig. 3C). All these cell lines showed *PCDH10* methylation in one or both alleles. None of the treatments had any effect on the level of expression of the control gene (Fig. 3C). Thus, these data establish that demethylation of the *PCDH10* promoter effectively reactivates gene expression by reversing the effect of methylation in cell lines. Overall, these data demonstrate that *PCDH10* down regulation in the majority of NHL cell lines is a consequence of promoter methylation.

***PCDH10* Inactivation Results in Increased Resistance to Doxorubicin in NHL Cell Lines**

Since the DNA promoter methylation of specific genes plays a significant role in tumorigenic processes and response to treatment, we examined the effects of *PCDH10* promoter methylation and its associated gene silencing on treatment response using a panel of NHL cell lines after exposure to commonly used drugs for the treatment of lymphoid malignancies. We tested all 20 NHL cell lines for cytotoxicity by MTT assay and analyzed the data on the basis of methylation of one or both alleles to defined doses of doxorubicin, dexamethasone, bortezomib, methotrexate, and L-asparaginase. Since all NHL cell lines showed either one or both copies methylated, we used two unmethylated leukemia cell lines (MOLT16 and T-ALL) as controls (Narayan et al., 2011). The only drug that showed differential cytotoxicity based on the promoter methylation status was doxorubicin (Figs. 4A and 4B). Other drugs did not exhibit detectable differences in cytotoxicity based on methylation status (Supporting Information Figs. 5A–5D). Of the 10 B-NHL cell lines tested, nine had homozygous methylation and one cell line (Farage) showed both methylated and unmethylated alleles. The nine B-NHL cell lines with homozygous methylation showed significantly lower cytotoxic effects compared with the cell line (Farage) that showed heterozygous methylation ($P = 0.009$). Both groups of B-NHL cell lines were more resistant to doxorubicin treatment compared with unmethylated leukemia cell lines (Fig. 4A). Of the 10 T-NHL cell lines tested, six cell lines showed homozygous methylation and the other four cell lines showed heterozygous methylation. Similar to the B-NHL cell lines, the T-NHL cell lines with both methylated alleles were significantly resistant to doxorubicin compared with the heterozygous methylated cell lines ($P = 0.002$) and unmethylated leukemia cell lines (Fig. 4B). A similar trend for doxorubicin resistance was found when the cell lines were analyzed based on detectable transcripts of *PCDH10* gene. Of the nine B-NHL cell lines with complete methylation, three cell lines (Raji, SUDHL-5, and LY-3) showing detectable levels of *PCDH10* transcripts were significantly ($P = 0.009$) sensitive to doxorubicin treatment compared with six cell lines that showed no detectable levels of expression (Fig. 4C). Similarly, seven T-NHL cell lines (MT2, CJ/M5, ED, SLB1, H9, HUT-78, and FE-PD) that showed detectable levels of variant 1 or 2 were more sensitive to doxorubicin treatment




Figure 4. Analysis of cell cytotoxicity in NHL cell lines exposed to leukemic drugs in relation to methylation and silencing of *PCDH10* gene. Viability assay showing cell survival in B-NHL (A) and T-NHL cell lines (B) in relation to methylation status. Viability assay showing cell survival in B-NHL cell lines (C) and T-NHL cell lines (D) in relation to

variant 2 mRNA expression. *P* values are shown above each comparison. UM/UM, both alleles unmethylated in leukemia cell lines; UM/M, both unmethylated and methylated alleles present; M/M, both alleles are methylated; V2-, no expression of variant 2; V2+, detectable levels of variant 2 expression.




Figure 5. Doxorubicin response to cell death by apoptosis analysis in NHL cell lines in relation epigenetic silencing of *PCDH10*. (A). Flow cytometric analysis of two cell lines showing high frequency of cell death in *PCDH10* expressed (H9) cell line compared with nonexpressed cell line (SUDHL-8). (B). Histogram showing significant differ-

ences cell death response to doxorubicin treatment in *PCDH10* expressing cell lines compared with nonexpresser cell lines. Ctrl, Control; DOX, doxorubicin; V1/2, variant 1 and 2. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

compared with three cell lines (MT1, TLOm1, and HH) that did not express *PCDH10* ($P = 0.01$) (Fig. 4D). Similar to methylation, other drugs did not exhibit detectable differences in cytotoxicity based on expression levels (Supporting Information Figs. 5E–5H). These data suggest that *PCDH10* transcriptional down-regulation has a causal affect on doxorubicin-induced cell lethality in NHL cell lines.

We next asked if a similar difference in resistance could be seen in the apoptotic response to doxorubicin treatment. To examine this, we tested two cell lines (H9 and HUT-78) expressing both variants and two cell lines (SUDHL-8 and WSU) with undetectable expression (Fig. 5A). The former had higher fraction of apoptotic cells com-

pared with nonexpresser cell lines after treatment with doxorubicin (Fig. 5B). To examine further the relationship between methylation status on apoptotic response, we tested all the five drugs on 11 to 17 NHL cell lines. We found significantly reduced apoptosis in all methylated NHL cell lines compared with unmethylated leukemia cell lines (Fig. 6). Also NHL cell lines with homozygous methylation were significantly resistant to apoptosis induction to dexamethasone and methotrexate treatments compared with the cell lines that showed heterozygous methylation (Figs. 6B and 6D). However, other drugs did not show significant difference in apoptotic response based on heterozygous and homozygous methylation status (Figs. 6A, 6C, and 6E). These data suggest




Figure 6. Flow cytometry analysis of apoptotic response in NHL (both B- and T-) cell lines exposed to leukemic drugs in relation to methylation of *PCDH10* gene. Histograms showing apoptotic response after exposure to doxorubicin (A, 17 cell lines), dexamethasone (B, 15 cell lines), bortezomib (C, 15 cell lines), methotrexate (D, 11 cell

lines), L-asparaginase (E, 15 cell lines). P values are shown above each comparison. UM/UM, both alleles unmethylated in leukemia cell lines; UM/M, both unmethylated and methylated alleles present; M/M, both alleles are methylated.

significantly reduced apoptotic response in *PCDH10* inactivated cell lines. Together, our data demonstrate that methylation-mediated inactivation of *PCDH10* negatively influences cellular response to doxorubicin treatment and possibly other drugs in NHL cell lines.

DISCUSSION

Cadherins play an important role in tumor progression by functioning as suppressors of invasion and metastasis (Jeanes et al., 2008). The *PCDH10* gene has shown to be inactivated by promoter methylation in a variety of tumors (Waha et al., 2005; Imoto et al., 2006; Yu et al., 2008, 2009; Narayan et al., 2009, 2011; Cheung et al., 2010). Over expression of this gene significantly inhibits proliferation of solid tumor cells in vitro, supporting its tumor suppressor function (Ying et al., 2006). To examine the role of *PCDH10* in mature lymphoid malignancies, we systematically analyzed qualitative and quantitative promoter hypermethylation in a large cohort of non-Hodgkin lymphomas, including cell lines, and multiple myelomas. Our present finding of high levels of promoter methylation in the vast majority of primary high-grade mature B- and T-cell lymphomas and their derived cell lines substantiate the prior findings that *PCDH10* is frequently methylated in different subtypes of malignant lymphomas (Ying et al., 2007). We have previously shown that epigenetic changes in the promoter of *PCDH10* preferentially occur in lymphoid-lineage leukemias compared with myeloid-lineage leukemias (Narayan et al., 2011). The present findings combined with our previous data suggest that *PCDH10* methylation is a unique phenomenon in all lymphoid lineage hematologic malignancies. Furthermore, the iden-

tification of promoter hypermethylation in 29% of RL/FH specimens and evidence of promoter methylation preceding chromosomal translocation in RL/FH suggest that inactivation of this gene occurs early and is likely a critical alteration during the neoplastic transformation of mature lymphoid cells.

NHL represents a highly diverse group of malignancies of both B- and T-cell lineages that comprise of different histologic subtypes. The malignant transformation of precursor cells is driven by errors in the machinery that regulates antibody diversification and lineage-specification cause specific chromosomal translocations and oncogenic mutations (Kuppers and Dalla-Favera, 2001). The landscape of genetic lesions in NHL is highly characteristic of specific histologic subtypes and several of the recurrent mutations have been shown to be driver mutations that play a critical role in lymphoma initiation (Shaffer et al., 2012). More recent studies have uncovered structural alterations in genes that regulate chromatin modifications such as *BMI1*, *EZH2*, *MLL2*, *CREBBP*, and *EP300* (Shaffer et al., 2012). The natural course of the different histologic subtypes of NHL is highly variable, ranging from indolent, like in CLL or FL, to highly aggressive, like in BL. The prognosis is also highly variable to current modalities of chemotherapy, radiation and the anti-CD20 antibody (Rituximab) treatment (Shaffer et al., 2012). Although specific genetic changes are diagnostic of specific lymphoma, biomarkers of therapeutic response are lacking in NHL.

DNA methylation and chromatin modifications dictate the biological behavior and response to therapy of cancer cells. Although, in the present study, we identified *PCDH10* methylation in

various NHL histologic subtypes, it was more frequently observed in lymphomas showing evidence of germinal center transit (BL, FL, DLBCL, MZL, and MCL) and T-cell lymphomas compared with nongermlinal center origin lymphomas (CLL and MM). Moreover, the levels of promoter methylation were not significantly different among indolent (FL) and aggressive (BL and DLBCL) type lymphomas. Based on these observations, combined with the finding that reactive lymph nodes harboring high-level methylation could progress to frank lymphoma, we propose a hypothesis that *PCDH10* methylation might represent an important early event in lymphomagenesis.

Although the role of *PCDH10* in cancer has not been fully elucidated, evidence for the epigenetic silencing of this gene contributing to tumorigenesis has been established (Ying et al., 2006). More recently, *PCDH10* was reported to be methylated in early stages of gastric carcinogenesis and its methylation was associated with poor prognosis in gastric cancer patients (Yu et al., 2009). Since *PCDH10* is a target of epigenetic silencing in the majority of lymphomas, its implications for chemotherapy response was examined. Although the mechanisms underlying cellular resistance to apoptosis in lymphomas remain unclear, our finding of resistance to cytotoxicity and decreased apoptotic response to doxorubicin treatment suggests that *PCDH10* methylation and inactivation in cell lines might play a role in chemotherapy resistance. Doxorubicin, a cellular target of topoisomerase-2 (Top2), is a widely used chemotherapeutic drug in many cancer types, including lymphomas. Doxorubicin binds to both DNA and Top2 forming doxorubicin-DNA adducts that initiates caspase cascade dependent apoptosis (Swift et al., 2006). The biologic basis of *PCDH10*-related resistance mechanisms and cooperation with other genetic/epigenetic pathways in chemoresistance of NHL remains to be determined. Ultimately designing successful epigenetic induction therapies similar to myeloid leukemias is a major challenge for therapy involving epigenetic agents in NHL.

In summary, this study has demonstrated the occurrence of epigenetic silencing of *PCDH10* in a high proportion of NHL and its likely onset at an early stage of lymphomagenesis suggesting a role for *PCDH10* in lymphoma development. The finding of doxorubicin resistance in association with *PCDH10* inactivation may have relevance in further exploring the role of epigenetic alterations and ultimately in establishing epigenetic therapies in lymphomas.

REFERENCES

- Baylin SB, Jones PA. 2011. A decade of exploring the cancer epigenome—Biological and translational implications. *Nat Rev Cancer* 11:726–734.
- Cheung HH, Lee TL, Davis AJ, Taft DH, Rennert OM, Chan WY. 2010. Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. *Br J Cancer* 102:419–427.
- Dyomin VG, Palanisamy N, Lloyd KO, Dyomina K, Jhanwar SC, Houldsworth J, Chaganti RS. 2000. MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. *Blood* 95:2666–2671.
- Garcia-Manero G, Yang H, Kuang SQ, O'Brien S, Thomas D, Kantarjian H. 2009. Epigenetics of acute lymphocytic leukemia. *Semin Hematol* 46:24–32.
- Imoto I, Izumi H, Yokoi S, Hosoda H, Shibata T, Hosoda F, Ohki M, Hirohashi S, Inazawa J. 2006. Frequent silencing of the candidate tumor suppressor *PCDH10* by epigenetic mechanism in non-small-cell lung cancers. *Cancer Res* 66:4617–4626.
- Jeanes A, Gottardi CJ, Yap AS. 2008. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? *Oncogene* 27:6920–6929.
- Kuppers R, Dalla-Favera R. 2001. Mechanisms of chromosomal translocations in B cell lymphomas. *Oncogene* 20:5580–5594.
- Li Y, Yang ZS, Song JJ, Liu Q, Chen JB. 2012. Protocadherin-10 is involved in angiogenesis and methylation correlated with multiple myeloma. *Int J Mol Med* 29:704–710.
- Narayan G, Scotto L, Neelakantan V, Kottoor SH, Wong AH, Loke SL, Mansukhani M, Pothuri B, Wright JD, Kaufmann AM, Schneider A, Arias-Pulido H, Tao Q, Murty VV. 2009. Protocadherin *PCDH10*, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer. *Genes Chromosomes Cancer* 48:983–992.
- Narayan G, Freddy AJ, Xie D, Liyanage H, Clark L, Kisselev S, Un Kang J, Nandula SV, McGuinn C, Subramaniyam S, Alobeid B, Satwani P, Savage D, Bhagat B, Murty VV. 2011. Promoter methylation-mediated inactivation of *PCDH10* in acute lymphoblastic leukemia contributes to chemotherapy resistance. *Genes Chromosomes Cancer* 50:1043–1053.
- Nowak D, Stewart D, Koeffler HP. 2009. Differentiation therapy of leukemia: 3 Decades of development. *Blood* 113:3655–3665.
- Pinkerton PH, Reis MD, DeCoteau J, Strigley JR, Dube ID, London B. 1992. A lineage-specific t(1;14)(q21;q32) as an early event in development of B-cell clonal expansion. *Cancer Genet Cytogenet* 64:166–169.
- Seton-Rogers S. 2012. Lymphoma: Epigenetic therapy gains momentum. *Nat Rev Cancer* 12:798–799.
- Shaffer AL, 3rd, Young RM, Staudt LM. 2012. Pathogenesis of human B cell lymphomas. *Annu Rev Immunol* 30:565–610.
- Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: International Agency for Research on Cancer. pp. 180–319.
- Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM. 2006. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. *Cancer Res* 66:4863–4871.
- Vakiani E, Nandula SV, Subramaniyam S, Keller CE, Alobeid B, Murty VV, Bhagat G. 2007. Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. *Hum Pathol* 38:315–325.
- Waha A, Guntner S, Huang TH, Yan PS, Arslan B, Pietsch T, Westler OD. 2005. Epigenetic silencing of the protocadherin family member *PCDH-gamma-A11* in astrocytomas. *Neoplasia* 7:193–199.
- Yagi T. 2008. Clustered protocadherin family. *Dev Growth Differ* 50(Suppl 1):S131–S140.
- Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, Putti T, Murray P, Chan AT, Tao Q. 2006. Functional epigenetics identifies a protocadherin *PCDH10* as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. *Oncogene* 25:1070–1080.
- Ying J, Gao Z, Li H, Srivastava G, Murray PG, Goh HK, Lim CY, Wang Y, Marafioti T, Mason DY, Ambinder RF, Chan AT, Tao Q. 2007. Frequent epigenetic silencing of protocadherin 10 by

- methylation in multiple haematologic malignancies. *Br J Haematol* 136:829–832.
- Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM, Jin H, To KF, Chan FK, Sung JJ. 2009. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. *Gastroenterology* 136:640–651.
- Yu JS, Koujak S, Nagase S, Li CM, Su T, Wang X, Keniry M, Memeo L, Rojzman A, Mansukhani M, Hibshoosh H, Tycko B, Parsons R. 2008. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. *Oncogene* 27: 4657–4665.
- Zain J, O'Connor OA. 2010. Targeting histone deacetylases in the treatment of B- and T-cell malignancies. *Invest New Drugs* 28(Suppl 1):S58–S78.